Digital Medical Products

Digital Medical Products (DMPs) encompass a broad category of software and digital tools with an intended medical purpose, such as Software as a Medical Device (SaMD), AI-powered diagnostic imaging systems, and digital therapeutics. Their classification is primarily governed by regulations like the EU Medical Device Regulation (MDR, 2017/745), which categorizes devices based on risk. With the advent of the EU AI Act, most DMPs incorporating AI will also be classified as 'high-risk AI systems,' subjecting them to dual regulatory scrutiny. In enterprise risk management, this means compliance cannot solely rely on medical device standards like ISO 13485 (Quality Management Systems) and IEC 62304 (Software Lifecycle). Companies must now integrate the AI Act's stringent requirements for risk management, data governance, technical documentation, transparency, and post-market monitoring, creating a comprehensive, dual-track compliance framework to mitigate legal and safety risks.

In enterprise risk management, applying a structured approach to DMP compliance is crucial. The process involves three key steps: 1. **Dual Classification:** First, determine if the product qualifies as a medical device under EU MDR (2017/745) and establish its risk class (e.g., I, IIa, IIb). Concurrently, assess it against the EU AI Act's criteria (Annex III) to determine if it's a high-risk AI system. An AI for cancer diagnosis, for instance, would be both. 2. **Integrated Conformity Assessment:** Develop a unified Quality Management System (QMS) compliant with ISO 13485 that also incorporates the AI Act's requirements for data quality, robustness, and cybersecurity. The technical documentation must satisfy both regulations. 3. **Enhanced Post-Market Surveillance (PMS):** Implement a proactive PMS system as mandated by both MDR (Article 83) and the AI Act (Article 61). This system must monitor not only device safety but also ongoing AI model performance, drift, and bias. Following this integrated process can significantly improve efficiency, with companies reporting up to a 20% reduction in regulatory review times and achieving a 100% audit pass rate.

Taiwanese enterprises face several key challenges when bringing DMPs to the EU market. 1. **Dual Regulatory Complexity:** Navigating the intricate, overlapping requirements of the EU MDR and the AI Act creates a significant compliance burden and increases costs. 2. **Data Governance:** Meeting the AI Act's strict standards for high-quality, representative, and unbiased training data is difficult, often hindered by inconsistent local data formats and Taiwan's Personal Data Protection Act. 3. **Talent Scarcity:** There is a shortage of professionals with cross-disciplinary expertise in medical device regulation, AI ethics, and cybersecurity. To overcome these, companies should: 1. **Adopt an Integrated Compliance Framework:** Conduct a gap analysis to merge AI Act requirements into the existing ISO 13485 QMS. 2. **Form Strategic Data Partnerships:** Collaborate with medical centers to establish ethical, compliant data-sharing protocols. 3. **Invest in Expertise:** Build internal capabilities through training and engage external consultants to bridge knowledge gaps, aiming to establish a core AI governance team within six months.

Winners Consulting specializes in digital medical products for Taiwan enterprises, delivering compliant management systems within 90 days. Free consultation: https://winners.com.tw/contact